Results with ENBREL in
Ankylosing Spondylitis (AS)
In 2003, ENBREL became the first biologic approved as a treatment option for ankylosing spondylitis (AS).
In medical studies, ENBREL has been shown to significantly reduce the symptoms
of ankylosing spondylitis. Many AS patients using ENBREL experienced a greater reduction in back pain (including nighttime pain), inflammation, and morning stiffness; improved spinal mobility; and an improvement in the ability to do everyday tasks. ENBREL was shown to be effective in about 3 out of 5 adults. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.
Your results may vary. Because ENBREL works on the immune system, it can lower the ability of your immune system to fight infections and may raise other safety concerns.
Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.